Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Randomized Controlled Trial Comparing Underwater Versus Conventional Preventive Coagulation for Intraprocedural Vessel Management During Peroral Endoscopic Myotomy (POEM)

8 de mayo de 2026 actualizado por: Mohan Ramchandani, Asian Institute of Gastroenterology, India

Peroral Endoscopic Myotomy (POEM) has become an established, minimally invasive therapy for achalasia and esophageal motility disorders. Submucosal tunnelling is a critical phase of POEM and requires meticulous haemostasis to avoid bleeding, loss of orientation, reduced visibility, and prolonged procedural time.

The current standard method of vessel coagulation during POEM involves conventional coagulation under CO₂ insufflation using the hybrid knife (HK). However, this approach can require additional hemostatic devices-most commonly coagulation forceps-particularly when dealing with large-calibre vessels or resistant bleeding.

A novel technique-underwater preventive coagulation-leverages water as a conductive medium. Preliminary evidence suggests that:

  • electrosurgical current in water is focalized at the interface of the vessel,
  • allowing a soft sealing of the vessel wall,
  • reducing the risk of vessel rupture or unintended deep thermal injury,
  • and potentially eliminating the need to convert to coagulation forceps. Pilot data from our center demonstrate that underwater prophylactic sealing of large vessels during POEM is feasible, safe, and associated with markedly reduced need for rescue coagulation forceps. The technique is already used in practice but lacks systematic evidence from prospective randomized trials.

This study is designed to provide high-quality evidence on whether underwater vessel coagulation improves haemostatic efficiency, reduces intra-procedural bleeding, and minimizes device changes during POEM.

All POEM procedures will be performed under general anesthesia in the supine position using Fujifilm high-definition gastroscopes with a 2.8 mm channel and transparent distal cap.

Steps (Both Arms)

  1. Identify the esophagogastric junction (EGJ).
  2. Inject saline + methylene blue submucosally.
  3. Create a 2 cm mucosal incision at 5-6 o'clock position, 10 cm above EGJ.
  4. Enter the submucosal space.
  5. Perform submucosal tunnelling down to EGJ and 2-3 cm into cardia.

  6. Perform vessel haemostasis according to group allocation:

    • Underwater coagulation (intervention)
    • CO₂-based conventional coagulation (control)
  7. Perform circular myotomy (with occasional full-thickness myotomy when indicated).
  8. Close the mucosal entry using hemostatic clips.
  9. Record procedure time, instrument exchanges, bleeding events, and forceps usage.

Equipment

  • Hybrid Knife (Erbe Elektromedizin GmbH)
  • VIO 3 generator + ERBEJet 2 water-jet system
  • Methylene-blue tinted saline
  • Electrosurgical settings: ENDO CUT Q 2-3-3 for mucosal incision and myotomy

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Primary Objective

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1. Underwater preventive vessel coagulation, and 2. Conventional vessel coagulation under CO₂ insufflation. Secondary Objectives

  1. To compare composite forceps use (rescue + prophylactic) between groups.
  2. To evaluate the frequency of prophylactic-only forceps use.
  3. To compare total number of forceps applications per procedure.
  4. To determine differences in intra-procedural bleeding episodes.
  5. To compare procedural efficiency (procedure time, number of instrument exchanges).
  6. To compare hematological and inflammatory markers (Hb drop, Hct, CRP, WBC).
  7. To compare delayed bleeding rates within 30 days.
  8. To evaluate overall complication rates (intra- and post-procedural).
  9. To assess patient-reported outcomes (pain, tolerability). A prospective, randomized, open-label, parallel-group, controlled clinical trial.

Study Arms Intervention Arm: Underwater Coagulation

  • Vessel coagulation performed entirely underwater using the Hybrid Knife.
  • SWIFT COAG: E3 (89 W) for POEM.
  • Physiological saline instilled to completely displace air around the target vessel.

Control Arm: Conventional Coagulation (CO₂ Setting)

  • Standard vessel isolation and coagulation under CO₂ insufflation.
  • SWIFT COAG: E3 (89 W) for POEM.

Tipo de estudio

De observación

Inscripción (Estimado)

120

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Rajesh Goud Mr Maragoni, M.Pharm
  • Número de teléfono: 312 04023378888
  • Correo electrónico: rajeshgoud761@gmail.com

Copia de seguridad de contactos de estudio

  • Nombre: Zaheer Nabi Dr Mohammed, MD DNB
  • Número de teléfono: 427 04023378888
  • Correo electrónico: zaheernabi1978@gmail.com

Ubicaciones de estudio

  • India
    • Telangana
      • Hyderabad, Telangana, India, 500082
        • Reclutamiento
        • Asian Institute of Gastroenterology Hospital
        • Contacto:
        • Contacto:
          • Rajesh Goud Mr Maragoni, M.Pharm MBA
          • Número de teléfono: 301 04023378888
          • Correo electrónico: rajeshgoud761@gmail.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Método de muestreo

Muestra de probabilidad

Población de estudio

120 (60 in each arm)

Descripción

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Diagnosis of achalasia or esophageal motility disorder planned for POEM
  3. Ability to provide informed consent

Exclusion Criteria:

  1. Anticoagulant or antithrombotic therapy not safely stoppable
  2. Known coagulopathy or platelet disorder
  3. Esophageal/gastric varices
  4. Previous POEM or Heller's myotomy
  5. Prior treatment for same condition
  6. Inability or refusal to consent
  7. Visualized vessels smaller than the HK inner diameter (1.2 mm)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Under Water Coagulation

Intervention Arm: Underwater Coagulation

  • Vessel coagulation performed entirely underwater using the Hybrid Knife.
  • SWIFT COAG: E3 (89 W) for POEM.
  • Physiological saline instilled to completely displace air around the target vessel.
Otro: Under Water Preventive Coagulation

Leverages water as a conductive medium. Preliminary evidence suggests that:

  1. electrosurgical current in water is focalized at the interface of the vessel,
  2. allowing a soft sealing of the vessel wall,
  3. reducing the risk of vessel rupture or unintended deep thermal injury,
  4. and potentially eliminating the need to convert to coagulation forceps.
Conventional Coagulation

Control Arm: Conventional Coagulation (CO₂ Setting)

  • Standard vessel isolation and coagulation under CO₂ insufflation.
  • SWIFT COAG: E3 (89 W) for POEM.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:
Periodo de tiempo: 60 minutes
  1. Underwater preventive vessel coagulation, and
  2. Conventional vessel coagulation under CO₂ insufflation.
60 minutes

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To compare composite forceps use (rescue + prophylactic) between groups.
Periodo de tiempo: 60 minutes

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
60 minutes
To evaluate the frequency of prophylactic-only forceps use.
Periodo de tiempo: 60 minutes

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
60 minutes
To compare total number of forceps applications per procedure.
Periodo de tiempo: 60 minutes

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
60 minutes
To determine differences in intra-procedural bleeding episodes
Periodo de tiempo: 60 minutes

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
60 minutes
To compare procedural efficiency (procedure time, number of instrument exchanges
Periodo de tiempo: 60 minutes

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
60 minutes
To compare hematological and inflammatory markers (Hb drop, Hct, CRP, WBC)
Periodo de tiempo: 24 hours

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
24 hours
To compare delayed bleeding rates
Periodo de tiempo: 30 days
To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
30 days
To evaluate overall complication rates (intra- and post-procedural)
Periodo de tiempo: 24 hours

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
24 hours
To assess patient-reported outcomes (pain, tolerability).
Periodo de tiempo: 72 hours

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
72 hours

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Asian Institute of Gastroenterology, India

Investigadores

  • Director de estudio: Mohan Dr Ramchandani, MD DM, Asian Institute of Gastroenterology

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de febrero de 2026

Finalización primaria (Estimado)

10 de mayo de 2027

Finalización del estudio (Estimado)

30 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

4 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

4 de mayo de 2026

Publicado por primera vez (Actual)

8 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

8 de mayo de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • POEM UWC 2026

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir